Consequently, the expression levels of C3aR and C5aR also showed correspondingly increases in patients with stage 4 CKD, especially in the ESRD group (P = 0.005 and < 0.001, compared to the non-ESRD group, respectively). This evidence concerns the gene C5AR1 and chronic kidney disease.